Reports Q3 revenue $97.8M, consensus $93.42M. “It is immensely gratifying to see a growing number of DEB patients worldwide benefit from access to VYJUVEK, and we look forward to rapidly and sustainably expanding that number in the months ahead,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech (KRYS). “With multiple near-term readouts, starting with cystic fibrosis in Q4, and a strong balance sheet, Krystal is well positioned to advance our pipeline and deliver transformative therapies to patients with serious and rare diseases.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- KRYS Earnings this Week: How Will it Perform?
- Krystal Biotech’s Promising Lung Cancer Study: A Potential Game-Changer?
- Krystal Biotech’s KB407 Study: A Promising Step for Cystic Fibrosis Treatment
- Krystal Biotech’s Innovative Approach to Treating Alpha-1 Antitrypsin Deficiency: A Clinical Update
- Krystal Biotech Advances DEB Research with New Observational Study